CLINICAL_TRIALS
trial_result
· 2014-03-03
Clinical Trial Update: Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 [Phase 2]
Summary
Phase 2 trial of Dovitinib (TKI258) in imatinib/sunitinib-resistant gastrointestinal stromal tumors has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2014-03-03